{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-22-000033","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.044277+00:00","generated_at":"2026-06-24T05:41:12.862729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook","bullets":["Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).","Net loss $14.6M ($0.40/share) vs $13.0M ($0.36/share) in Q2 2021.","Gross margin improved to 75% from 74% due to production efficiencies.","Added 18 new U.S. treatment centers (total 248); cash $166.8M.","FY2022 revenue guidance reaffirmed $55M-$60M; operating expenses $100M-$105M."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-22-000033","json":"https://secwatch.observer/filing/0001127537-22-000033.json","markdown":"https://secwatch.observer/filing/0001127537-22-000033.md","text":"https://secwatch.observer/filing/0001127537-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/0001127537-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000033/lung-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:41:12.862729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}